Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012.
Necchi A, Lo Vullo S, Bregni M, Rosti G, Mariani L, Raggi D, Giannatempo P, Secondino S, Schumacher K, Massard C, Kanfer E, Oechsle K, Laszlo D, Michieli M, Ifrah N, Mercier M, Crysandt M, Wuchter P, Nagler A, Wahlin A, Martino M, Badoglio M, Pedrazzoli P, Lanza F; European Society for Blood and Marrow Transplantation (EBMT) Solid Tumors Working Party. Necchi A, et al. Among authors: mariani l. Clin Genitourin Cancer. 2017 Feb;15(1):163-167. doi: 10.1016/j.clgc.2016.06.013. Epub 2016 Jun 27. Clin Genitourin Cancer. 2017. PMID: 27444987
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
Morabito A, Gattuso D, Stani SC, Fanelli M, Ferraù F, De Sio L, Castellana MA, Lorusso V, Priolo D, Vitale S, Sarmiento R, Lo Vullo S, Mariani L, Gasparini G. Morabito A, et al. Among authors: mariani l. Breast Cancer Res Treat. 2004 Aug;86(3):249-57. doi: 10.1023/B:BREA.0000036898.45123.e9. Breast Cancer Res Treat. 2004. PMID: 15567941 Clinical Trial.
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M. Gasparini G, et al. Among authors: mariani l. Cancer J. 2005 May-Jun;11(3):209-16. doi: 10.1097/00130404-200505000-00007. Cancer J. 2005. PMID: 16053664 Clinical Trial.
1,179 results